Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

238 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer.
Hudelist G, Köstler WJ, Czerwenka K, Kubista E, Attems J, Müller R, Gschwantler-Kaulich D, Manavi M, Huber I, Hoschützky H, Zielinski CC, Singer CF. Hudelist G, et al. Among authors: attems j. Int J Cancer. 2006 Mar 1;118(5):1126-34. doi: 10.1002/ijc.21492. Int J Cancer. 2006. PMID: 16161043 Free article. Clinical Trial.
Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment.
Hudelist G, Köstler WJ, Attems J, Czerwenka K, Müller R, Manavi M, Steger GG, Kubista E, Zielinski CC, Singer CF. Hudelist G, et al. Among authors: attems j. Br J Cancer. 2003 Sep 15;89(6):983-91. doi: 10.1038/sj.bjc.6601160. Br J Cancer. 2003. PMID: 12966413 Free PMC article.
The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status.
Köstler WJ, Brodowicz T, Hudelist G, Rudas M, Horvat R, Steger GG, Singer CF, Attems J, Rabitsch W, Fakhrai N, Elandt K, Wiltschke C, Hejna M, Zielinski CC. Köstler WJ, et al. Among authors: attems j. J Cancer Res Clin Oncol. 2005 Jul;131(7):420-8. doi: 10.1007/s00432-005-0670-3. Epub 2005 Apr 29. J Cancer Res Clin Oncol. 2005. PMID: 15864644
Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2 mutations.
Hudelist G, Wagner T, Rosner M, Fink-Retter A, Gschwantler-Kaulich D, Czerwenka K, Kroiss R, Tea M, Pischinger K, Köstler WJ, Attems J, Mueller R, Blaukopf C, Kubista E, Hengstschläger M, Singer CF. Hudelist G, et al. Among authors: attems j. Endocr Relat Cancer. 2007 Dec;14(4):1053-62. doi: 10.1677/ERC-06-0075. Endocr Relat Cancer. 2007. PMID: 18045956
High-level ERBB2 gene amplification is associated with a particularly short time-to-metastasis, but results in a high rate of complete response once trastuzumab-based therapy is offered in the metastatic setting.
Fuchs EM, Köstler WJ, Horvat R, Hudelist G, Kubista E, Attems J, Zielinski CC, Singer CF. Fuchs EM, et al. Among authors: attems j. Int J Cancer. 2014 Jul 1;135(1):224-31. doi: 10.1002/ijc.28660. Epub 2014 Jan 28. Int J Cancer. 2014. PMID: 24311197 Free article.
PTEN expression as a predictor for the response to trastuzumab-based therapy in Her-2 overexpressing metastatic breast cancer.
Gschwantler-Kaulich D, Tan YY, Fuchs EM, Hudelist G, Köstler WJ, Reiner A, Leser C, Salama M, Attems J, Deutschmann C, Zielinski CC, Singer CF. Gschwantler-Kaulich D, et al. Among authors: attems j. PLoS One. 2017 Mar 2;12(3):e0172911. doi: 10.1371/journal.pone.0172911. eCollection 2017. PLoS One. 2017. PMID: 28253285 Free PMC article.
Alzheimer pathology in the olfactory bulb.
Jellinger KA, Attems J. Jellinger KA, et al. Among authors: attems j. Neuropathol Appl Neurobiol. 2005 Apr;31(2):203. doi: 10.1111/j.1365-2990.2004.00619.x. Neuropathol Appl Neurobiol. 2005. PMID: 15771713 No abstract available.
238 results